Plain-English translation of NCT05800210 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a stem cell transplant procedure that uses the Miltenyi CliniMACS Prodigy® system to remove specific immune cells from donor stem cells before transplanting them into patients with blood cancers. The goal is to see if removing these cells makes the transplant safer and more effective. Researchers want to understand whether this approach reduces serious complications while still helping the transplanted cells fight the cancer.
Stem cell transplants can cure many blood cancers, but they often cause serious side effects when the donor immune cells attack the patient's body. This trial is exploring whether removing certain immune cells beforehand can reduce these dangerous complications while keeping the cancer-fighting benefits.
You likely qualify if…
You likely don't qualify if…
You will receive a preparatory treatment regimen followed by an infusion of the specially processed stem cells from your matched donor. The trial will monitor your safety and how well the transplanted cells engraft and work against your cancer through regular blood tests, imaging, and clinic visits. Your medical team will track you closely for any side effects and measure whether the treatment helps control or cure your disease.
AI-generated summary from trial data · Jun 24, 2026 · Not medical advice
United States